Literature DB >> 23411486

HPV L1 detection discriminates cervical precancer from transient HPV infection: a prospective international multicenter study.

Grit Mehlhorn1, Ellen Obermann, Giovanni Negri, Lukas Bubendorf, Christine Mian, Martin Koch, Heinz Sander, Birgit Simm, Markus Lütge, Zsuzsanna Bánrévi, Anke Weiss, Gieri Cathomas, Ralf Hilfrich, Matthias Wilhelm Beckmann, Henrik Griesser.   

Abstract

The benefits of cytology-based cervical cancer screening programs in reducing morbidity and mortality are well recognized. Especially, overtreatment of human papillomavirus (HPV) high-risk positive early dysplastic lesions may have a negative impact on reproductive outcomes for fertile women. To optimize the clinical management an objective standard is needed to distinguish precancer that requires treatment, from spontaneously resolving HPV infections. In the current study, we examined the prognostic relevance of HPV-L1 capsid protein analysis with Cytoactiv in an international prospective multicenter study including 908 HPV high-risk positive early dysplastic lesions (LSIL/HSIL) during a follow-up period of 54 months. The clinical end points of the study were histologically confirmed CIN3+ as progression, CIN1/2 for stable disease and repeated negative Pap smears as spontaneous clinical remission. The difference of the clinical outcome of HPV-L1-negative and HPV-L1-positive cases was statistically highly significant (P-value<0.0001) independent of the classification as mild dysplasia (LSIL) and moderate dysplasia (HSIL). Of the HPV-L1-negative HPV high-risk positive mild/moderate dysplasias 84% progressed to CIN3, as compared with only 20% of the HPV-L1-positive cases. The data from our study show that HPV-L1 detection allows to identify transient HPV infections and precancerous lesions within the group of HPV high-risk positive early dysplastic lesions. The high progression rate of HPV-L1-negative mild and moderate dysplasia emphasizes the precancerous nature of these lesions. A close follow-up with colposcopy and histological evaluation is advisable and removal of these lesions should be considered. The low malignant potential of HPV-L1-positive cases, however, indicates transient HPV infection, justifying a watch and wait strategy with cytological follow-up, thus preventing overtreatment especially for women in their reproductive age.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23411486     DOI: 10.1038/modpathol.2012.233

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  5 in total

Review 1.  [Who performs gynecological cytology and how?].

Authors:  D Schmidt; H H Neumann
Journal:  Pathologe       Date:  2015-11       Impact factor: 1.011

2.  Risk stratification of cervical disease using detection of human papillomavirus (HPV) E4 protein and cellular MCM protein in clinical liquid based cytology samples.

Authors:  Andrew Stevenson; Kim Kavanagh; Jiafeng Pan; Lynne Stevenson; Heather Griffin; John Doorbar; Evelyn Scott; Miriam Deeny; Kate Cuschieri; Sheila V Graham
Journal:  J Clin Virol       Date:  2018-08-31       Impact factor: 3.168

3.  Establishment of epigenetic markers to predict irradiation efficacy against oropharyngeal cancer.

Authors:  Tomoya Kurokawa; Takuya Nakagawa; Keisuke Matsusaka; Masaki Fukuyo; Masato Mima; Kiyoshi Misawa; Bahityar Rahmutulla; Jun-Ichiro Ikeda; Toyoyuki Hanazawa; Yoshitaka Okamoto; Atsushi Kaneda
Journal:  Cancer Sci       Date:  2020-02-27       Impact factor: 6.716

4.  DRH1 - a novel blood-based HPV tumour marker.

Authors:  Thomas Weiland; Alexander Eckert; Peter Valentin Tomazic; Axel Wolf; Prisca Pondorfer; Sarah Vasicek; Matthias Graupp; Clemens Holzmeister; Ulrich Moser; Alexandros Andrianakis; Georg Kangler; Peter Kiss; Luka Brcic; Matthias Kappler; Claudia Wickenhauser; Anja Haak; Maximilian Krüger; Bilal Al-Nawas; Sebastian Blatt; Norbert Brockmeyer; Adriane Skaletz-Rorowski; Anja Potthoff; Lars E French; Sara Charnowski; Markus Reinholz; Andreas M Kaufmann; Sarah Thies; Hans-Georg Lambrecht; Barbara Seliger; Dominik C Wild; Dietmar Thurnher
Journal:  EBioMedicine       Date:  2020-06-11       Impact factor: 8.143

5.  Use of Cap Analysis Gene Expression to detect human papillomavirus promoter activity patterns at different disease stages.

Authors:  Ayumi Taguchi; Kazunori Nagasaka; Charles Plessy; Hiroe Nakamura; Yoshiko Kawata; Sachi Kato; Kosuke Hashimoto; Takeshi Nagamatsu; Katsutoshi Oda; Iwao Kukimoto; Kei Kawana; Piero Carninci; Yutaka Osuga; Tomoyuki Fujii
Journal:  Sci Rep       Date:  2020-10-22       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.